Assuming Co-PSMA trial is favourable and CLARIFY provides sufficient evidence from safety/ efficacy and other factors, could they approach FDA for approval in the pre-prostratectomy market first and then simultaneously start AMPLIFY phase 3 to move into an earlier patient segment? I haven’t fully understood the rationale for delaying CLARIFY approval until AMPLIFY phase 3 completion.
While today’s Ann says phase 2 in DISCO can lead to phase 3 but doesn’t say the company is funded for it. So those kind of questions may create uncertainty IMO.
DYOR
CU6 Price at posting:
$2.20 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)